Embudo, Ziefforah A.

HRN: 21-63-93  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/17/2022
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
08/17/2022
08/24/2022
IV
53mg
Q24h
Soft Tissue Abscess
Waiting Final Action 
08/17/2022
AMPICILLIN 250MG (VIAL)
08/17/2022
08/24/2022
IV
175mg
Q6h
Soft Tissue Abscess
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: